Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Hi-Tech OTCs up slightly in fiscal 2013; Pharmstandard spins off OTC unit; Nu Skin raises estimates; infant formula makers respond to China inquiry; Pennsylvania joins NPLEx; and Everett alleges Acella infringes in prenatals.

You may also be interested in...



Rx-Only Pseudoephedrine Stalls As Meth Solution In Tennessee, Indiana

Tennessee’s meth lab seizures are up this year, but CHPA says that’s because more labs are uncovered through the state’s participation in the NPLEx stop-sale system. Rx-only bills have stalled in several states, including Indiana, where lawmakers passed a bill to cap PSE purchases at about 61 grams per year.

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip

With One Launch Under Way, SpringWorks Ramps Up For A Second

The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel